Cargando…

Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States

Randomized trials have shown marked reductions in low‐density lipoprotein cholesterol (LDL‐C), a risk factor for cardiovascular disease (CVD), when evolocumab is administered. We hypothesized that evolocumab added to standard of care (SOC) vs SOC alone is cost‐effective in the treatment of patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gandra, Shravanthi R., Villa, Guillermo, Fonarow, Gregg C., Lothgren, Mickael, Lindgren, Peter, Somaratne, Ransi, van Hout, Ben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2016
Materias:	Quality and Outcomes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074319/ https://www.ncbi.nlm.nih.gov/pubmed/27092712 http://dx.doi.org/10.1002/clc.22535

Ejemplares similares

Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting
por: Dent, Ricardo, et al.
Publicado: (2016)

Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden
por: Landmesser, Ulf, et al.
Publicado: (2020)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
por: Kasichayanula, Sreeneeranj, et al.
Publicado: (2018)

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety
por: Lee, Edward, et al.
Publicado: (2019)

Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia
por: Kuchimanchi, Mita, et al.
Publicado: (2018)

Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China
por: Wan, Yuansheng, et al.
Publicado: (2023)

Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE‐AF registry
por: Contreras, Johanna P., et al.
Publicado: (2019)

Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban
por: Tamayo, Sally, et al.
Publicado: (2015)

Association between anxiety and clinical outcomes in Chinese patients with myocardial infarction in the absence of obstructive coronary artery disease
por: He, Chao‐Jie, et al.
Publicado: (2020)

Time‐trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF‐STENT Registry
por: Boivin‐Proulx, Laurie‐Anne, et al.
Publicado: (2019)

Diabetes association with self‐reported health, resource utilization, and prognosis post‐myocardial infarction
por: Nicolau, José C., et al.
Publicado: (2020)

Percutaneous coronary intervention and 30‐day unplanned readmission with chest pain in the United States (Nationwide Readmissions Database)
por: Sykes, RobertA., et al.
Publicado: (2021)

Mortality and guideline‐directed medical therapy in real‐world heart failure patients with reduced ejection fraction
por: McCullough, Peter A., et al.
Publicado: (2021)

The impact of short hospital stay on prognosis after acute myocardial infarction: An analysis from the ACSIS database
por: Tomer, Orr, et al.
Publicado: (2021)

Device infections related to cardiac resynchronization therapy in clinical practice–An analysis of its prevalence, risk factors and routine surveillance at a single center university hospital
por: Ostrowska, Bozena, et al.
Publicado: (2021)

Gender differences in acute myocardial infarction—A nationwide German real‐life analysis from 2014 to 2017
por: Kuehnemund, Leonie, et al.
Publicado: (2021)

Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study
por: Rosenson, Robert S., et al.
Publicado: (2019)

Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure
por: Nath, Mintu, et al.
Publicado: (2022)

C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV
por: Nelson, Adam J., et al.
Publicado: (2020)

Acute and chronic impact of cardiovascular events on health state utilities
por: Matza, Louis S, et al.
Publicado: (2015)

Effects of Evolocumab on Cardiovascular Events
por: Mikhail, Nasser
Publicado: (2017)

A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies
por: Koren, Michael J., et al.
Publicado: (2020)

Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
por: Gibbs, John P., et al.
Publicado: (2016)

A Retrospective Study to Examine Healthcare Costs Related to Cardiovascular Events in Individuals with Hyperlipidemia
por: Henk, Henry J., et al.
Publicado: (2015)

Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline
por: Journath, Gunilla, et al.
Publicado: (2017)

Erratum to: ‘Costs of treating cardiovascular events in Germany: a systematic literature review’
por: Schmid, Tamara, et al.
Publicado: (2016)

Medical costs associated with cardiovascular events among high-risk patients with hyperlipidemia
por: Bonafede, Machaon M, et al.
Publicado: (2015)

Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia
por: Toth, Peter P., et al.
Publicado: (2017)

The economic considerations of patients and caregivers in choice of dialysis modality
por: Walker, Rachael C., et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada
por: Grégoire, Jean, et al.
Publicado: (2022)

Patient-level costs of major cardiovascular conditions: a review of the international literature
por: Nicholson, Gina, et al.
Publicado: (2016)

Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*
por: Borissov, Borislav, et al.
Publicado: (2017)

Productivity loss and indirect costs associated with cardiovascular events and related clinical procedures
por: Song, Xue, et al.
Publicado: (2015)

Development and Validation of a High‐Quality Composite Real‐World Mortality Endpoint
por: Curtis, Melissa D., et al.
Publicado: (2018)

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy
por: Jetty, Vybhav, et al.
Publicado: (2017)

Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial
por: Shah, Syed Raza, et al.
Publicado: (2017)

Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
por: Fogacci, Federica, et al.
Publicado: (2021)

Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
por: Fogacci, Federica, et al.
Publicado: (2021)

Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk
por: Quek, Ruben G W, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nm8b3pa1deb5obmmsfahmpgtsf